Navigation Links
Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Date:1/3/2013

Seattle, Washington (PRWEB) January 03, 2013

Biosim Pharmaceuticals LLC (http://www.biosimllc.com) today announced it will be participating in the Biotech Showcase 2013 on January 7th-9th. The Biotech showcase, held alongside the JP Morgan 2013 Healthcare Conference in San Francisco, brings together biopharmaceutical executives from around the world into a collaborative learning environment.

Biosim Pharmaceuticals, LLC will be scheduling private one to one meetings with partners and interested companies throughout the conference regarding Biosim's flagship product, a generic ACTHAR gel. The brand H.P. ACTHAR gel is a highly purified corticotrophin gelatin depot formulation manufactured by Questcor Pharmaceuticals for the treatment of infantile spasms, multiple sclerosis, nephrotic syndrome and rheumatic disorders. Please contact bd(at)biosimllc(dot)com to schedule a meeting.

About BioSim Pharmaceuticals:
BioSim (biosimllc.com), a Seattle-based pharmaceutical company, focuses on building a portfolio of generic drugs for the orphan disease markets. BioSim consists of a team of highly capable individuals working together to implement both the near, and long-term objectives of advancing our pre-clinical and clinical development, all the way through late-stage development.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10286464.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
2. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
3. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
4. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
5. Biosimilars: Global Markets
6. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... the re-launch of “Crosswalk Insight: Oncology™” (Crosswalk), a unique precision medicine knowledge visualization ... can now be accessed through Inspirata’s diagnostic cockpit and is downloadable as an ...
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath ... associated with peritoneal dialysis, announced today that it has published the result of ... in Peritoneal Dialysis International (PDI), the official Journal of the International Society ...
(Date:2/20/2017)...  Atrius Health and IBM (NYSE: IBM ... to develop a cloud based service designed to ... view of the multiple influences on an individual,s ... be designed to support shared decision making between ... nonprofit healthcare organization with 875 physicians caring for ...
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT ... the Center for International Blood & Marrow Transplant Research (CIBMTR) will take place ... , The combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research ...
Breaking Biology Technology:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):